Recombinant BCG as a candidate oral vaccine vector

R. G. Barletta, B. Snapper, J. D. Cirillo, N. D. Connell, D. D. Kim, W. R. Jacobs, B. R. Bloom

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Bacille Calmette-Guerin (BCG), currently the most widely used vaccine in the world, was originally administered for many years as an oral vaccine. The low frequency of serious complications, inexpensive production, and adjuvanticity make BCG an ideal candidate for a recombinant vaccine vehicle. Although mycobacteria are slow growing and not yet well characterized genetically, we have recently developed technology for the genetic manipulation of BCG and other mycobacteria. Phage and plasmid systems based on a shuttle strategy to manipulate DNA in Escherichia coli and transfer it to mycobacteria have been developed. We have established that the aminoglycoside phosphotransferase gene can be used as an effective selectable marker in the mycobacteria and that a foreign antigen from Mycobacterium leprae can be expressed in BCG. Furthermore, a thorough analysis of mycobacterial expression sequences has been undertaken to optimize the expression of foreign antigens in BCG. We constructed an expression probe shuttle plasmid with β-galactosidase as reporter gene, and have used it successfully to identify multiple mycobacteriophage DNA sequences with varying levels of constitutive or regulable promotor activity. Further genetic advances required for development of recombinant BCG into an effective recombinant vaccine vehicle, including possibilities for oral administration, are adumbrated.

Original languageEnglish (US)
Pages (from-to)931-939
Number of pages9
JournalResearch in Microbiology
Volume141
Issue number7-8
DOIs
StatePublished - Jan 1 1990

Fingerprint

Mycobacterium
Vaccines
Synthetic Vaccines
Plasmids
Mycobacteriophages
Galactosidases
Kanamycin Kinase
Antigens
Mycobacterium leprae
Reporter Genes
Bacteriophages
Oral Administration
Escherichia coli
Technology
DNA
Genes

Keywords

  • Bacille Calmette-Guerin, Recombinant oral vaccine, Shuttle vector
  • β-Galactosidase, Mycobacteria

ASJC Scopus subject areas

  • Microbiology
  • Molecular Biology

Cite this

Barletta, R. G., Snapper, B., Cirillo, J. D., Connell, N. D., Kim, D. D., Jacobs, W. R., & Bloom, B. R. (1990). Recombinant BCG as a candidate oral vaccine vector. Research in Microbiology, 141(7-8), 931-939. https://doi.org/10.1016/0923-2508(90)90132-A

Recombinant BCG as a candidate oral vaccine vector. / Barletta, R. G.; Snapper, B.; Cirillo, J. D.; Connell, N. D.; Kim, D. D.; Jacobs, W. R.; Bloom, B. R.

In: Research in Microbiology, Vol. 141, No. 7-8, 01.01.1990, p. 931-939.

Research output: Contribution to journalArticle

Barletta, RG, Snapper, B, Cirillo, JD, Connell, ND, Kim, DD, Jacobs, WR & Bloom, BR 1990, 'Recombinant BCG as a candidate oral vaccine vector', Research in Microbiology, vol. 141, no. 7-8, pp. 931-939. https://doi.org/10.1016/0923-2508(90)90132-A
Barletta RG, Snapper B, Cirillo JD, Connell ND, Kim DD, Jacobs WR et al. Recombinant BCG as a candidate oral vaccine vector. Research in Microbiology. 1990 Jan 1;141(7-8):931-939. https://doi.org/10.1016/0923-2508(90)90132-A
Barletta, R. G. ; Snapper, B. ; Cirillo, J. D. ; Connell, N. D. ; Kim, D. D. ; Jacobs, W. R. ; Bloom, B. R. / Recombinant BCG as a candidate oral vaccine vector. In: Research in Microbiology. 1990 ; Vol. 141, No. 7-8. pp. 931-939.
@article{175a3ae4072a4192968e16384473ffbd,
title = "Recombinant BCG as a candidate oral vaccine vector",
abstract = "Bacille Calmette-Guerin (BCG), currently the most widely used vaccine in the world, was originally administered for many years as an oral vaccine. The low frequency of serious complications, inexpensive production, and adjuvanticity make BCG an ideal candidate for a recombinant vaccine vehicle. Although mycobacteria are slow growing and not yet well characterized genetically, we have recently developed technology for the genetic manipulation of BCG and other mycobacteria. Phage and plasmid systems based on a shuttle strategy to manipulate DNA in Escherichia coli and transfer it to mycobacteria have been developed. We have established that the aminoglycoside phosphotransferase gene can be used as an effective selectable marker in the mycobacteria and that a foreign antigen from Mycobacterium leprae can be expressed in BCG. Furthermore, a thorough analysis of mycobacterial expression sequences has been undertaken to optimize the expression of foreign antigens in BCG. We constructed an expression probe shuttle plasmid with β-galactosidase as reporter gene, and have used it successfully to identify multiple mycobacteriophage DNA sequences with varying levels of constitutive or regulable promotor activity. Further genetic advances required for development of recombinant BCG into an effective recombinant vaccine vehicle, including possibilities for oral administration, are adumbrated.",
keywords = "Bacille Calmette-Guerin, Recombinant oral vaccine, Shuttle vector, β-Galactosidase, Mycobacteria",
author = "Barletta, {R. G.} and B. Snapper and Cirillo, {J. D.} and Connell, {N. D.} and Kim, {D. D.} and Jacobs, {W. R.} and Bloom, {B. R.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1016/0923-2508(90)90132-A",
language = "English (US)",
volume = "141",
pages = "931--939",
journal = "Research in Microbiology",
issn = "0923-2508",
publisher = "Elsevier Masson SAS",
number = "7-8",

}

TY - JOUR

T1 - Recombinant BCG as a candidate oral vaccine vector

AU - Barletta, R. G.

AU - Snapper, B.

AU - Cirillo, J. D.

AU - Connell, N. D.

AU - Kim, D. D.

AU - Jacobs, W. R.

AU - Bloom, B. R.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Bacille Calmette-Guerin (BCG), currently the most widely used vaccine in the world, was originally administered for many years as an oral vaccine. The low frequency of serious complications, inexpensive production, and adjuvanticity make BCG an ideal candidate for a recombinant vaccine vehicle. Although mycobacteria are slow growing and not yet well characterized genetically, we have recently developed technology for the genetic manipulation of BCG and other mycobacteria. Phage and plasmid systems based on a shuttle strategy to manipulate DNA in Escherichia coli and transfer it to mycobacteria have been developed. We have established that the aminoglycoside phosphotransferase gene can be used as an effective selectable marker in the mycobacteria and that a foreign antigen from Mycobacterium leprae can be expressed in BCG. Furthermore, a thorough analysis of mycobacterial expression sequences has been undertaken to optimize the expression of foreign antigens in BCG. We constructed an expression probe shuttle plasmid with β-galactosidase as reporter gene, and have used it successfully to identify multiple mycobacteriophage DNA sequences with varying levels of constitutive or regulable promotor activity. Further genetic advances required for development of recombinant BCG into an effective recombinant vaccine vehicle, including possibilities for oral administration, are adumbrated.

AB - Bacille Calmette-Guerin (BCG), currently the most widely used vaccine in the world, was originally administered for many years as an oral vaccine. The low frequency of serious complications, inexpensive production, and adjuvanticity make BCG an ideal candidate for a recombinant vaccine vehicle. Although mycobacteria are slow growing and not yet well characterized genetically, we have recently developed technology for the genetic manipulation of BCG and other mycobacteria. Phage and plasmid systems based on a shuttle strategy to manipulate DNA in Escherichia coli and transfer it to mycobacteria have been developed. We have established that the aminoglycoside phosphotransferase gene can be used as an effective selectable marker in the mycobacteria and that a foreign antigen from Mycobacterium leprae can be expressed in BCG. Furthermore, a thorough analysis of mycobacterial expression sequences has been undertaken to optimize the expression of foreign antigens in BCG. We constructed an expression probe shuttle plasmid with β-galactosidase as reporter gene, and have used it successfully to identify multiple mycobacteriophage DNA sequences with varying levels of constitutive or regulable promotor activity. Further genetic advances required for development of recombinant BCG into an effective recombinant vaccine vehicle, including possibilities for oral administration, are adumbrated.

KW - Bacille Calmette-Guerin, Recombinant oral vaccine, Shuttle vector

KW - β-Galactosidase, Mycobacteria

UR - http://www.scopus.com/inward/record.url?scp=0025597140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025597140&partnerID=8YFLogxK

U2 - 10.1016/0923-2508(90)90132-A

DO - 10.1016/0923-2508(90)90132-A

M3 - Article

C2 - 2101484

AN - SCOPUS:0025597140

VL - 141

SP - 931

EP - 939

JO - Research in Microbiology

JF - Research in Microbiology

SN - 0923-2508

IS - 7-8

ER -